| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,623 |
1,493 |
$101K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,543 |
1,429 |
$58K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
524 |
496 |
$32K |
| 87428 |
|
493 |
457 |
$23K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
713 |
682 |
$23K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
721 |
670 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,212 |
1,131 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
601 |
279 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
53 |
46 |
$639.60 |
| 81003 |
|
12 |
12 |
$10.38 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
154 |
145 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
154 |
145 |
$0.00 |